Previous 10 | Next 10 |
home / stock / azn / azn articles
AstraZeneca Plc (NASDAQ: AZN) discontinued the STABILIZE-CKD and DIALIZE-Outcomes Phase 3 evidence trials for Lokelma (sod...
In the ever-changing and fiercely competitive business landscape, conducting thorough company analysis is crucial for investors and industry expert...
The U.S. Centers for Disease Control and Prevention (CDC) released more than 77,000 additional doses of Beyfortus (nirsevimab), a respira...
The FDA approved Bristol Myers Squibb And Co's (NYSE: BMY) Augtyro (repotrectinib) for the treatment of adult patients with locally a...
Execution of binding subsequent investment agreement regarding contemplated additional equity investment of $140M by AstraZeneca, previously anno...
AstraZeneca Plc (NASDAQ: AZN) said its PACIFIC-2 Phase 3 trial for Imfinzi (durvalumab) concurrently administered with chemoradiothe...
In the dynamic and cutthroat world of business, conducting thorough company analysis is essential for investors and industry experts. In this artic...
The stock markets is in a lackluster session on Thursday, with traders eagerly awaiting more clues on monetary policy from Fed Chair Jerome Powell,...
AstraZeneca Plc (NASDAQ: AZN) has reported Q3 FY23 core EPS of $1.73, up 4% Y/Y (+9% on constant currency). On the ADR basis, core e...
News, Short Squeeze, Breakout and More Instantly...
2024-07-20 00:14:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-07-02 08:30:07 ET Jefferies analyst issues HOLD recommendation for AZN on July 2, 2024 06:20AM ET. The previous analyst recommendation was Hold. AZN was trading at $77.94 at issue of the analyst recommendation. The overall analyst consensus : BUY. Current analys...